BioSpace News Archive

Diarrhea remains the top health issue facing Americans traveling to high risk countries, affecting 30 to 70 per cent of travelers depending upon their destination, according to biopharmaceutical company Immuron Limited

SteriView™ www.steriviewinc.com announced today the Launch of its SteriCam™1.8mm Inspection Camera

NEWPORT BEACH, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its fourth quarter and full year 2019 financial results and provide a business update on Tuesday, February 25, 2020 prior to open of the U.S. financial markets. Management will host a conference call and live webcast to discuss Evolus’ financial results at 8:00 a.m.

Lianluo Smart Limited (“Lianluo Smart” or the “Company”) (NASDAQ: LLIT), a China based professional smart service and products provider announced today it has entered into a securities purchase agreement with certain accredited investors to purchase approximately $2.2 million of its Class A Common Shares

Feb. 12, 2020 17:35 UTC Company’s unique approach to medical device, and clinical and general IoT security provides healthcare organizations with total network visibility NEW YORK--( BUSINESS WIRE )-- Medigate , the first dedicated healthcare IoT security and asset management platform, today announced it was named to the Constellation ShortList™ for Medical Device Security in Q1 2020. Medigate’s unique platform enables accurate and comprehensive device discovery of conne

The PAST Foundation and Battelle announced that a $400,000 grant from Battelle will expand the “Innovation in Teaching” Fellowship program.

Dr. Lara G. Bakaeen recognized by the premier organization for prosthodontics.

Leading alternative protein producer Calysta has appointed Thomas JG Huot, Ph.D. as its Chief Operating Officer to lead global operations and corporate development activities.

According to the Amputee Coalition, up to 85% of the 2 million amputees living in the United States suffer from chronic pain, commonly referred to as phantom limb pain or residual limb pain, and the number of amputees in the U.S. is expected to grow to 3.6 million by 20501.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that researchers from the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital presented positive interim data from two ongoing Phase I/II clinical trials evaluating ABO-102 and ABO-101, the Company’s investigational gene therapies for MPS IIIA and MPS IIIB, respectively, at WORLDSymposium™